TY - JOUR T1 - Gastric Cancer: Identification of microRNAs Inhibiting Druggable Targets and Mediating Efficacy in Preclinical <em>In Vivo</em> Models JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 497 LP - 514 DO - 10.21873/cgp.20275 VL - 18 IS - 4 AU - ULRICH H. WEIDLE AU - FABIAN BIRZELE AU - ULRICH BRINKMANN AU - SIMON AUSLAENDER Y1 - 2021/07/01 UR - http://cgp.iiarjournals.org/content/18/4/497.abstract N2 - In addition to chemotherapy, targeted therapies have been approved for treatment of locally advanced and metastatic gastric cancer. The therapeutic benefit is significant but more durable responses and improvement of survival should be achieved. Therefore, the identification of new targets and new approaches for clinical treatment are of paramount importance. In this review, we searched the literature for down-regulated microRNAs which interfere with druggable targets and exhibit efficacy in preclinical in vivo efficacy models. As druggable targets, we selected transmembrane receptors, secreted factors and enzymes. We identified 38 microRNAs corresponding to the criteria as outlined. A total of 13 miRs target transmembrane receptors, nine inhibit secreted proteins and 16 attenuate enzymes. These microRNAs are targets for reconstitution therapy of gastric cancer. Further target validation experiments are mandatory for all of the identified microRNAs. ER -